- Home
- WPP vs EWTX Comparison
WPP vs EWTX Comparison
Compare WPP & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | EWTX |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.3B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WPP | EWTX |
|---|---|---|
| Price | $28.59 | $37.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $24.47 | ★ $54.00 |
| AVG Volume (30 Days) | 326.8K | ★ 1.2M |
| Earning Date | 08-06-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.81 | $16.70 |
| 52 Week High | $28.03 | $48.51 |
Technical Indicators
Market Signals| Indicator | WPP | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 40.86 |
| Support Level | $24.31 | $37.33 |
| Resistance Level | $27.74 | $41.13 |
| Average True Range (ATR) | 0.69 | 1.93 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 78.41 | 22.47 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.